12:00 AM
Aug 21, 2006
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RP101: Phase II start

By early next year, AVTO will begin a Phase II trial comparing 750 mg daily of RP101 plus gemcitabine to...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >